BC
MRSN

Boxer Capital’s Mersana Therapeutics MRSN Stock Holding History

Boxer Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-72,680
Closed -$3.43M – 30
2024
Q3 		$3.43M Buy
+72,680
New +$3.21M 0.17% 57
2023
Q4 		– Sell
-80,000
Closed -$2.54M – 63
2023
Q3 		$2.54M Buy
80,000
+40,000
+100% +$1.9M 0.14% 55
2023
Q2 		$3.29M Buy
+40,000
New +$5.85M 0.15% 59
2019
Q4 		– Sell
-67,232
Closed -$2.66M – 54
2019
Q3 		$2.66M Sell
67,232
-16,128
-19% -$1.17M 0.19% 44
2019
Q2 		$8.44M Buy
+83,360
New +$9.82M 0.73% 26

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Boxer Capital's MRSN Position: Q4 2024 in Review

Boxer Capital sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 72,680 shares — an estimated $3.43M sold.

Boxer Capital first reported a position in MRSN in Q2 2019 and held it in 5 quarters. The position peaked at $8.44M in Q2 2019. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Boxer Capital reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 72,680 Mersana Therapeutics shares in Q4 2024, an estimated $3.43M.
  • Boxer Capital first reported a position in Mersana Therapeutics in Q2 2019 and held it in 5 quarters.
  • Boxer Capital's Mersana Therapeutics position peaked at $8.44M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.